Healthcare provider profile · identity verified

Ashwani Kumar, MD

Family Practice · MADISONVILLE, KY · NPI 1851528509

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	488	68
Atorvastatin Calcium	Atorvastatin Calcium	465	91
Eliquis	Apixaban	283	60
Furosemide	Furosemide	259	72
Potassium Chloride	Potassium Chloride	248	45
Lisinopril	Lisinopril	229	41
Levothyroxine Sodium	Levothyroxine Sodium	209	49
Gabapentin	Gabapentin	178	51
Pantoprazole Sodium	Pantoprazole Sodium	164	60
Amlodipine Besylate	Amlodipine Besylate	161	51
Carvedilol	Carvedilol	154	37
Mirtazapine	Mirtazapine	154	31
Tramadol Hcl	Tramadol Hcl	135	31
Lorazepam	Lorazepam	123	28
Sertraline Hcl	Sertraline Hcl	112	24
Losartan Potassium	Losartan Potassium	110	31
Oxycodone Hcl	Oxycodone Hcl	108	19
Metoprolol Succinate	Metoprolol Succinate	104	40
Metoprolol Tartrate	Metoprolol Tartrate	101	20
Clopidogrel	Clopidogrel Bisulfate	100	29
Quetiapine Fumarate	Quetiapine Fumarate	95	15
Trazodone Hcl	Trazodone Hcl	82	18
Citalopram Hbr	Citalopram Hydrobromide	80	17
Escitalopram Oxalate	Escitalopram Oxalate	75	13
Tamsulosin Hcl	Tamsulosin Hcl	73	18
Buspirone Hcl	Buspirone Hcl	71	14
Divalproex Sodium	Divalproex Sodium	70	suppressed
Duloxetine Hcl	Duloxetine Hcl	70	20
Ondansetron Hcl	Ondansetron Hcl	70	47
Memantine Hcl	Memantine Hcl	68	11
Enulose	Lactulose	66	15
Donepezil Hcl	Donepezil Hcl	64	16
Myrbetriq	Mirabegron	63	suppressed
Levetiracetam	Levetiracetam	62	13
Jardiance	Empagliflozin	60	21
Ciprofloxacin Hcl	Ciprofloxacin Hcl	59	34
Amiodarone Hcl	Amiodarone Hcl	55	25
Xarelto	Rivaroxaban	53	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	52	14
Triamcinolone Acetonide	Triamcinolone Acetonide	48	17
Entresto	Sacubitril/Valsartan	45	11
Baclofen	Baclofen	43	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	43	suppressed
Finasteride	Finasteride	42	suppressed
Cephalexin	Cephalexin	40	19
Simvastatin	Simvastatin	40	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	39	38
Metformin Hcl	Metformin Hcl	38	16
Spironolactone	Spironolactone	36	24
Cefdinir	Cefdinir	35	26
Hydrochlorothiazide	Hydrochlorothiazide	34	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	34	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	16
Prednisone	Prednisone	31	23
Morphine Sulfate Er	Morphine Sulfate	30	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	29	suppressed
Valacyclovir	Valacyclovir Hcl	29	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	28	24
Celecoxib	Celecoxib	28	suppressed
Clonazepam	Clonazepam	28	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Diltiazem Hcl	Diltiazem Hcl	26	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	26	16
Levofloxacin	Levofloxacin	26	14
Prazosin Hcl	Prazosin Hcl	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	16
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Acetic Acid	Acetic Acid	24	suppressed
Metformin Hcl Er	Metformin Hcl	24	suppressed
Morphine Sulfate	Morphine Sulfate	24	20
Olanzapine	Olanzapine	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Restasis	Cyclosporine	22	suppressed
Risperidone	Risperidone	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Spiriva Handihaler	Tiotropium Bromide	21	suppressed
Lamotrigine	Lamotrigine	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Latanoprost	Latanoprost	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	15
Insulin Lispro Kwikpen U-100	Insulin Lispro	18	suppressed
Primidone	Primidone	18	suppressed
Arformoterol Tartrate	Arformoterol Tartrate	17	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Isosorbide Mononitrate	Isosorbide Mononitrate	17	suppressed
Valsartan	Valsartan	17	suppressed
Digoxin	Digoxin	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	13
Incruse Ellipta	Umeclidinium Bromide	16	suppressed
Alphagan P	Brimonidine Tartrate	15	suppressed
Atenolol	Atenolol	15	suppressed
Baqsimi	Glucagon	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Lacosamide	Lacosamide	15	suppressed
Clindamycin Hcl	Clindamycin Hcl	14	suppressed
Lurasidone Hcl	Lurasidone Hcl	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Nystatin	Nystatin	14	12
Venlafaxine Hcl	Venlafaxine Hcl	14	suppressed
Methimazole	Methimazole	13	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	13	11
Alprazolam	Alprazolam	12	suppressed
Balsalazide Disodium	Balsalazide Disodium	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Gemtesa	Vibegron	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Carbamazepine	Carbamazepine	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Ramipril	Ramipril	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error